

AMENDMENTS TO THE SPECIFICATION:

In compliance with 37 C.F.R. § 1.821-1.825, please substitute the attached paper copy of the Sequence Listing in place of the Sequence Listing originally filed. No new matter has been added to the Sequence Listing.

Please amend the specification as shown:

On page 4, line 23 to page 5, line 7, please amend as follows:

In one aspect the present invention relates to the use of an antisecretory protein or homologues thereof having the same functional properties; or an oligo- or poly-peptide or derivatives thereof comprising an amino acid sequence of Formula I:

X1-V-C-X2-X3-K-X4-R-X5 (Formula I; SEQ ID NOS: 3-6)

wherein

X1 is I, amino acids nos. 1-35 of SEQ ID NO:1, or is absent

X2 is H, R or K

X3 is S or L

X4 is T or A

X5 is amino acids nos. 43-46 (SEQ ID NO: 3), 43-51 (SEQ ID NO: 4), 43-80 (SEQ ID NO: 5) or 43-163 (SEQ ID NO: 6) of SEQ ID NO:1, or is absent; or a pharmaceutically acceptable salt thereof;

in the manufacture of a medicament for the treatment and/or prevention of a condition associated with or characterised by rescue or by a pathological loss and/or gain of cells and/or brain oedema.

On page 9, line 21 to page 10, line 4, please amend as follows:

In a sixth aspect the present invention relates to a method of propagating, inducing, reducing and/or maintaining the genesis of an isolated stem cell and/or stem cell progeny from any germinal layer *in vitro*, characterised by treating the isolated cell with an antisecretory protein or homologues thereof having the same functional properties, or an oligo- or polypeptide or derivatives thereof comprising an amino acid sequence of Formula I:

X1-V-C-X2-X3-K-X4-R-X5 (Formula I; SEQ ID NOS: 3-6)

wherein

X1 is I, amino acids nos. 1-35 of SEQ ID NO:1, or is absent

X2 is H, R or K

X3 is S or L

X4 is T or A

X5 is amino acids nos. 43-46 (SEQ ID NO: 3), 43-51 (SEQ ID NO: 4), 43-80 (SEQ ID NO: 5) or 43-163 (SEQ ID NO: 6) of SEQ ID NO:1, or is absent, or a pharmaceutically acceptable salt thereof.

On page 10, line 21 to page 11, line 3, please amend as follows:

In a seventh aspect the present invention relates to a method of treatment and/or prevention of a condition associated with or characterised by a patholo-gical loss and/or gain of cells, comprising administering to a patient in need thereof an effective amount of an antisecretory protein, or an oligo- or polypeptide or derivatives thereof comp-rising an amino acid sequence of Formula I:

X1-V-C-X2-X3-K-X4-R-X5 (Formula I; SEQ ID NOS: 3-6)

wherein

X1 is I, amino acids nos. 1-35 of SEQ ID NO:1, or is absent

X2 is H, R or K

X3 is S or L

X4 is T or A

X5 is amino acids nos. 43-46 (SEQ ID NO: 3), 43-51 (SEQ ID NO: 4), 43-80 (SEQ ID NO: 5) or 43-163 (SEQ ID NO: 6) of SEQ ID NO:1, or is absent, or a pharmaceutically acceptable salt thereof.